In yesterday’s Wall Street session, GSK Plc ADR (NYSE:GSK) shares traded at $35.36, up 0.86% from the previous session.
GSK stock price is now 3.99% away from the 50-day moving average and -9.38% away from the 200-day moving average. The market capitalization of the company currently stands at $72.14B.
On November 12, 2024, Jefferies Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $53 to quote $39.50, while ‘Guggenheim’ rates the stock as ‘Neutral’
In other news, GSK plc, 10% Owner bought 2,791,930 shares of the company’s stock on Sep 27 ’24. The stock was bought for $22,335,440 at an average price of $8.00. Upon completion of the transaction, the 10% Owner now directly owns 16,775,691 shares in the company, valued at $593.19 million. A total of 0.00% of the company’s stock is owned by insiders.
During the past 12 months, GSK Plc ADR has had a low of $31.72 and a high of $45.92. As of last week, the company has a debt-to-equity ratio of 1.15, a current ratio of 0.81, and a quick ratio of 0.53. According to the stock market information, the enterprise value for the company is $155336802304, which is based on a 23.01 price-to-earnings ratio, a 4.93 price-to-earnings-growth ratio, and a beta of 0.64. The fifty day moving average price for GSK is $33.985 and a two-hundred day moving average price translates $39.0456 for the stock.
The latest earnings results from GSK Plc ADR (NYSE: GSK) was released for 2024-09-30. The net profit margin was 7.97% and return on equity was 18.18% for GSK. The company reported revenue of $10.42 billion for the quarter, compared to $10.31 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.04 percent.
